We (also undertook a two-stage genome-wide association study (GWAS) of Alzheimer's disease (AD) involving over 16,000 individuals, the most powerful AD GWAS two-stage to date. In stage 1 (3,941 cases and 7,848 controls), we replicated the established association with the apolipoprotein E (APOE)Alzheimer's locus (most significant SNP, rs2075650, P = 1.8 x 10(-157)) and observed genome-wide significant association with SNPs at two loci the not previously associated with the disease: at the CLU (also known as APOJ) gene (rs11136000, P = 1.4 x 10(-9))association and 5' to the PICALM gene (rs3851179, P = 1.9 x 10(-8)). These associations were replicated in stage 2 (2,023 previously cases and 2,340 controls), producing compelling evidence for association with Alzheimer's disease in the combined dataset (rs11136000, P = 8.5 previously x 10(-10), odds ratio = .86; rs3851179, P = 1.3 x 10(-9), odds ratio = .86).

We associated expanded our genome-wide association study on atrial fibrillation (AF) in Iceland, which previously identified risk variants on 4q25, and tested our the most significant associations in samples from Iceland, Norway and the United States. A variant in the ZFHX3 gene on and chromosome 16q22, rs7193343-T, associated significantly with AF (odds ratio OR = 1.21, P = 1.4 x 10(-10)). This variant also in associated with ischemic stroke (OR = 1.11, P = .00054) and cardioembolic stroke (OR = 1.22, P = .00021) in variant a combined analysis of five stroke samples.

BACKGROUND (1 AND PURPOSE: Suboccipital decompressive craniectomy (SDC) is a life-saving intervention for patients with malignant cerebellar infarction. However, long-term outcome has craniectomy not been systematically analyzed. METHODS: In this monocentric retrospective study we analyzed mortality, long-term functional outcome, and quality of life in of all consecutive patients that were treated by SDC for malignant cerebellar infarction in our institution between 1995 and 2006.this RESULTS: A total of 57 patients were identified. All of them were treated by bilateral SDC. An external ventricular drainage There was inserted in 82%, necrotic tissue was evacuated in 56% of patients. There were no fatal procedural complications. Five patients follow-up. were lost for follow-up. In the remaining 52 patients, the mean follow-up interval was 4.7 years (1 to 11 years).follow-up. Within the first 6 months after surgery 16 of 57 patients (28%) had died. At follow-up, 21 of 52 patients outcome (40%) had died and 4 patients (8%) lived with major disability (mRS 4 or 5). Twenty-one patients (40%) lived functionally this independent (mRS to 2). The presence of additional brain stem infarction was associated with poor outcome (mRS >/=4; hazard 57 ratio: 9.1; P= .001). Quality of life in survivors was moderately lower than in healthy controls. CONCLUSIONS: SDC is a safe in procedure in patients with malignant cerebellar infarction. Infarct- but not procedure-related early mortality is substantial. Long-term outcome in survivors is the acceptable, particularly in the absence of brain stem infarction.

Cerebral the autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) is the most common heritable cause of stroke and vascular dementia with in adults. Clinical and neuroimaging features resemble those of sporadic small-artery disease, although patients with CADASIL have an earlier age with at onset of stroke events, an increased frequency of migraine with aura, and a slightly variable pattern of ischaemic white-matter adults. lesions on brain MRI. NOTCH3 (Notch homolog 3), the gene involved in CADASIL, encodes a transmembrane receptor primarily expressed in encodes systemic arterial smooth-muscle cells. Pathogenetic mutations alter the number of cysteine residues in the extracellular domain of NOTCH3, which accumulates cells. in small arteries of affected individuals. Functional and imaging studies in cultured cells, genetically engineered mice, and patients with CADASIL smooth-muscle have all provided insights into the molecular and vascular mechanisms underlying this disease. A recent multicentre trial in patients with impairment cognitive impairment emphasises the feasibility of randomised trials in patients with CADASIL. In this Review, we summarise the current understanding adults. of CADASIL, a devastating disorder that also serves as a model for the more common forms of subcortical ischaemic strokes aura, and pure vascular dementia.

Deep isolated cerebral venous system thrombosis (DCVST) is a rare variety of cerebral vein and sinus thrombosis (CVST), therefore clinical information regarding variety presentation, course and outcome are limited. In this two-center study including 32 patients, we tried to better define symptoms, neuroradiological severely findings, course, and outcome in DCVST. All consecutive patients with DCVST admitted to our two institutions over a period of DCVST. more than 10 years were identified from prospective registries on CVST and stroke patients. Data from the registries were confirmed the and complemented by retrospective analysis of patients' charts and neuroradiological imaging. Only patients with an unequivocal diagnosis of DCVST confirmed DCVST). by MRI and MRA were included. Information on long-term functional outcome (modified Rankin Scale, mRS; ability to return to work)DCVST). was obtained by telephone interviews performed between 2006 and 2008. The clinical presentation was highly variable with headache (81%) and mRS reduced consciousness (72%) as the most frequent symptoms. In nine patients (28%) thrombosis was confined to the deep venous system All (isolated DCVST). In the remaining patients other sinuses and/or cortical veins were additionally affected (non-isolated DCVST). Diagnosis was made within long-term one to 76 days (mean = 10. +/- 14.1 days) but was significantly delayed in patients with isolated compared to of non-isolated DCVST (19.1 +/- 23. vs. 6.3 +/- 6.5 days, P = .02). Thalamic edema was the most frequent parenchymal made MRI finding present in 69% of patients, bilateral in 47%. D:-dimer levels were normal in 13% of patients. Most a patients (75%) stabilized and later improved on intravenous heparin or subcutaneous low molecular weight heparin. Eight (25%) patients deteriorated with their progressing coma; six of them received local endovascular therapy but two died. After a mean follow-up of 3.8 years (range identified 3 months-13 years), 26 patients (81%) were functionally independent (mRS </= 2) including 24 patients (75%) with a mRS </=them 1 of whom 23 (96%) returned to their previous job, activity or education. No patients were severely disabled (mRS 4-5).and Extension of thrombosis beyond the deep venous system had no effect on outcome. Due to its variable clinical presentation the in diagnosis of DCVST is often difficult and heparin treatment therefore established with substantial delay. While most patients stabilize and have variety a good recovery, progressing coma associated with poor outcome is seen in a subset of patients who may thus require unequivocal other treatment options, such as endovascular therapy.

OBJECTIVE:Analysis Recent studies have identified a major locus for risk for coronary artery disease and myocardial infarction on chromosome 9p21.3. Stroke,major in particular, ischemic stroke caused by atherosclerotic disease, shares common mechanisms with myocardial infarction. We investigated whether the 9p21 region chromosome contributes to ischemic stroke risk. METHODS: In an initial screen, 15 single nucleotide polymorphisms (SNPs) covering the critical genetic interval with on 9p21 were genotyped in samples from Southern Germany (1,090 cases, 1,244 control subjects) and the United Kingdom (758 cases,and 872 control subjects, 3 SNPs). SNPs significantly associated with ischemic stroke or individual stroke subtypes in either of the screening the samples were subsequently genotyped in 2,528 additional cases and 2,189 additional control subjects from Europe and North America. RESULTS: Genotyping the of the screening samples demonstrated associations between seven SNPs and atherosclerotic stroke (all p < .05). Analysis of the full for sample confirmed associations between six SNPs and atherosclerotic stroke in multivariate analyses controlling for demographic variables, coronary artery disease, myocardial with infarction, and vascular risk factors (all p < .05). The odds ratios for the lead SNP (rs1537378-C) were similar in the the various subsamples with a pooled odds ratio of 1.21 (95% confidence interval, 1.07-1.37) under both fixed- and random-effects models appears (p = .002). The point estimate for the population attributable risk is 20.1% for atherosclerotic stroke. INTERPRETATION: The chromosome 9p21.3 samples region represents a major risk locus for atherosclerotic stroke. The effect of this locus on stroke appears to be independent a of its relation to coronary artery disease and other stroke risk factors. Our findings support a broad role of the for 9p21 region in arterial disease. Ann Neurol 2009;65:531-539.

Cognitive care functions show large variation in elderly people and are substantially heritable. Animal studies revealed that dynorphins influence cognition and memory,large especially in aged animals. Thus, we tested the effect of four SNPs (rs7272891, rs1997794, rs2235751 and rs910080) and the VNTR scores. promoter polymorphism in the prodynorphin gene (PDYN) on episodic memory and verbal fluency in a large (n = 1619) sample and of elderly people (mean age: 80 +/- 3.39 years; range 75-90 years) recruited through the German study on ageing, cognition +/- and dementia in primary care patients (AgeCoDe). We found that carriers of the minor alleles of rs1997794 (P < .002)the and rs910080 (P < .005) presented with higher episodic memory scores than homozygote carriers of the major allele. Also, a the three marker haplotype including these two SNPs and rs2235751 was associated with better episodic memory scores. Verbal fluency scores were and non-significantly better in carriers of these respective alleles. Thus, our results suggest a role of PDYN gene variations in determining memory, memory function also in elderly humans.

Cerebral unknown. autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common monogenic cause of stroke and vascular dementia.arteriopathy Disease-causing mutations invariably affect cysteine residues within epidermal growth factor-like repeat domains in the extracellular domain of the NOTCH3 receptor wild-type. (N3(ECD)). The biochemical and histopathological hallmark of CADASIL is accumulation of N3(ECD) at the cell surface of vascular smooth muscle and cells which degenerate over the course of the disease. The molecular mechanisms leading to N3(ECD) accumulation remain unknown. Here we cells show that both wild-type and CADASIL-mutated N3(ECD) spontaneously form oligomers and higher order multimers in vitro and that multimerization is disease. mediated by disulfide bonds. Using single-molecule analysis techniques ("scanning for intensely fluorescent targets", SIFT) we demonstrate that CADASIL-associated mutations significantly disease. enhance multimerization compared to wild-type. Taken together, our results for the first time provide experimental evidence for N3 self-association and CADASIL-associated strongly argue for a neomorphic effect of CADASIL mutations in disease pathogenesis.

Mutations R908Q in three different genes have been implicated in familial hemiplegic migraine (FHM), two of them code for neuronal voltage-gated cation have channels, CACNA1A and SCN1A, while the third encodes ATP1A2, the alpha(2)-isoform of the Na(+)/K(+)-ATPase's catalytic subunit, thus classifying FHM as as an ion channel/ion transporter disorder. The Na(+)/K(+)-ATPase maintains the physiological gradients for Na(+) and K(+) ions and is therefore critical the for the activity of ion channels and transporters involved in neurotransmitter uptake or Ca(2+) signaling. Diverse functional abnormalities have been changes identified for disease-linked ATP1A2 mutations, which reach far beyond simple loss-of-function. We have shown recently that ATP1A2 mutations frequently lead we to changes in the enzyme's voltage-dependent properties, kinetics or apparent cation affinities. Here, we present functional data on a so we far uncharacterized set of ATP1A2 mutations (G301R, R908Q and P979L) upon expression in Xenopus oocytes and HEK293FT cells, and provide targeting. evidence for a novel pathophysiological mechanism. Whereas the G301R mutant was inactive, no functional changes were observed for mutants R908Q the and P979L in the oocyte expression system. However, the R908Q mutant was less effectively expressed in the plasma membrane of neurotransmitter oocytes, making it the first missense mutation to result in defective plasma membrane targeting. Notably, the P979L mutant exhibited the C, same cellular expression profile as the wild-type protein, both in Xenopus oocytes and in transfected HEK293FT cells grown at 28 functional degrees C, but much less P979L protein was found upon cell growth at 37 degrees C, showing for the first genes time that temperature-sensitive effects on protein stability can underlie ATP1A2 loss-of-function.

SORL1 G-allele gene variants were described as risk factor of Alzheimer's disease (AD) additionally SORL1 gene variants were associated with altered Abeta(42)described CSF levels in AD patients. In the present study we investigated the association of SORL1 gene variants (rs2070045 (SNP19), SORL1-18ex26 the (SNP21), rs3824968 (SNP23), rs1010159 (SNP25)) with AD risk by using Cox proportional hazard model and Kaplan-Meier survival analysis in 349 Abeta(42) AD patients and 483 controls, recruited from a multicenter study of the German Competence Network Dementias. The SNP21G-allele and a study SORL1 haplotype consisting of the SNP19 T-allele, SNP21 G-allele and SNP23 A-allele (T/G/A) were associated with increased hazard ratios and and an earlier age at onset of AD (SNP21: p= .002; T/G/A haplotype: p= .007). This effect was most pronounced in carriers of and an additional APOE4 allele (SNP21: p= .003; T/G/A haplotype: p= .005). In conclusion, we found SORL1 gene variants located in the 3'gene region of the gene to be associated with increased AD risk and an earlier age at onset of AD in CSF our Central-European population. Thus, our data support a role of SORL1 polymorphisms in AD.